CANNABIS SCIENCE, INC (CBIS) ENTERS $60 BILLION PET MARKET
November 25 2015 - 10:10AM
InvestorsHub NewsWire
ANALYST RECOMMENDS ‘ACCUMULATE’ AND $0.10 PPS
TARGET
500% ROI POTENTIAL
New
York, NY -- November 25, 2015 – Wall Street Corner just
released a Special Situation Report on Cannabis Science,
Inc. (OTC: CBIS), a
U.S. company specializing in the development of cannabis-based
medicines. The report comes in conjunction with the fully reporting
Company’s recent release of its most recent quarterly financial
report and announcement of entry into the $60 billion U.S. pet
market with a line of pet health products.
The analyst authoring the report
initiated coverage with an 'Accumulate' recommendation and a
near-term target price per share of $0.05 with a long term target
price per share of $0.10.
These analyses were supported by research showing
that Americans spent an all-time high of $55.7 billion on their
pets last year with expected spending to approach $60 billion this
year. Cannabis Science is very excited to enter into the
multi-billion dollar Animal Healthcare industry very soon through
their subsidiary, Equi-Pharm.
You can read this report in its entirety
at http://i-businessmanagementllc.com/uploads/documents/cbis-analyst-report.pdf
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding
of metabolic processes to provide novel treatment approaches to a
number of illnesses for which current treatments and understanding
remain unsatisfactory. Cannabinoids have an extensive history
dating back thousands of years, and currently, there are a growing
number of peer-reviewed scientific publications that document the
underlying biochemical pathways that cannabinoids modulate. The
Company works with leading experts in drug development, medicinal
characterization, and clinical research to develop, produce, and
commercialize novel therapeutic approaches for the treatment for
illnesses caused by infections as well as for age-related illness.
Our initial focus is on skin cancers, HIV/AIDS, and neurological
conditions. The Company is proceeding with the research and
development of its proprietary drugs as a part of this initial
focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Act of 1934. A statement containing words
such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements. Safe Harbor
Statement. The Private Securities Litigation Reform Act of 1995
provides a 'safe harbor' for forward-looking statements. Certain of
the statements contained herein, which are not historical facts are
forward looking statements with respect to events, the occurrence
of which involved risks and uncertainties. These forward-looking
statements may be impacted, either positively or negatively, by
various factors. Information concerning potential factors that
could affect the company are detailed from time to time in the
company's reports filed with the Securities and Exchange
Commission.
Wall Street
Corner
Larry
Oakley
info@wallstreetcornerreport.com
888-509-2165 ext. 102